Evotec and EQRx announce integrated drug discovery and development partnership

Biotech startup aims to deliver important new therapies to patients at more affordable prices

22-Nov-2021 - Germany

Evotec SE and EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, announced a collaboration to design, discover and develop new therapeutic options for patients. The collaboration will help accelerate EQRx’s pipeline expansion efforts by leveraging Evotec’s unique data-driven, fully integrated R&D-platform, applied across different drug modalities and therapeutic areas. This approach aims to expedite the invention and development of novel drugs and helps ensure superior translation from research ideas to safe and efficacious medicines.

pixabay.com

Symbolic image

The collaboration will focus on multiple therapeutic targets in oncology and immunology. Under the terms of the agreement, EQRx and Evotec will collaborate on drug discovery, pre-clinical and clinical development. Evotec will lead drug discovery and pre-clinical development efforts, and EQRx will be responsible for clinical development, regulatory and commercialisation efforts. In addition to jointly funded research and development activities, Evotec will benefit from the potential commercial success of the assets developed within the partnership through a variable profit share mechanism.

Dr Craig Johnstone, Chief Operating Officer of Evotec, commented: “EQRx’s ambitious and transformative mission to deliver important new therapies to patients at more affordable prices makes them an ideal partner for us. This exciting new partnership will expand the reach of our unique data-driven integrated R&D platform. We look forward to leveraging our combined knowledge, expertise and leading-edge technologies to advance new medicines against validated targets as rapidly as possible to make the biggest possible impact for patients.”

“We continue to rapidly expand our early-stage development pipeline through access to innovative, next-generation drug discovery and engineering technologies,” said Carlos Garcia-Echeverria, PhD, chief of Rx creation at EQRx. “This collaboration with Evotec will enable us to engineer and develop precision medicines in immunology and oncology with high quality and speed of execution. We look forward to a productive collaboration to bring innovative, affordable and accessible treatment options to people in need.” 

Other news from the department business & finance

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance

Something is happening in the life science industry ...

This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.